Rheumatology experts discuss challenge of selecting appropriate SSc patients with skin fibrosis for treatment
Search results for: scleroderma
Can Scleroderma Be Cured by Curing Cancer?
Research review
ACR/ARHP Annual Meeting 2012: Physicians Find Treatment Options Limited for Scleroderma Bowel Disease
With few proven medical treatments for scleroderma bowel disease, physicians often recommend a lifestyle change for patients as a first treatment option
Studies Show Promise for Scleroderma Therapy and Prediction of Progressing Disease
Research shows that a serum from goats might be helpful in combating diffuse cutaneous systemic sclerosis (SSc)
Pain Perspective in Scleroderma
Systemic sclerosis (SSc; scleroderma) is a disease in which inflammatory and fibrotic changes result in overproduction and accumulation of collagen and other extracellular matrix proteins, resulting in intimal vascular damage, fibrosis, and occasionally organ dysfunction affecting the gastrointestinal, lung, heart, and renal systems. There are two classifications of SSc—limited cutaneous or CREST (calcinosis, Raynaud’s, esophageal dysmotility, sclerodactyly, and telangectasias) syndrome, where skin thickening occurs mainly in the distal extremities and facial/neck areas and internal organ involvement, if present, occurs later in the disease process; and diffuse cutaneous disease where there is a more rapid progression of skin thickening from distal to proximal and organ involvement can be severe and occur early in the disease. As noted by various authors, there is no “crystal ball” into which one can look to see the outcome of the disease, and involvement varies significantly from one person to the next.
Can Technology Help Solve Scleroderma Renal Crisis?
A case study in using the Internet to facilitate rare disease research
Help Patients with Scleroderma Manage Musculoskeletal and Functional Limitations
On March 10, Janet Poole, PhD, OTR, professor of the occupational therapy graduate program at the University of New Mexico in Albuquerque, will continue the ARHP’s Audioconference/Webcast Series with the management of scleroderma. Dr. Poole received her BS in occupational therapy from Colorado State University, her MA degree in educational psychology from the University of North Carolina, Chapel Hill, and her PhD in motor learning/motor control from the University of Pittsburgh. Dr. Poole’s research interest is in scleroderma and the functional impact of the disease on the tasks of daily living, oral hygiene, parenting, and employment. She has conducted a number of studies examining rehabilitation interventions with people who have scleroderma and, with a colleague, is developing a self-management program for these patients. She has also authored several textbook chapters on rehabilitation for people with scleroderma.
Case Report: Complicated Presentation Eventually Explained by Rare Syndrome
Pachydermoperiostosis (PDP), also known as Touraine-Solente-Golé syndrome or primary hypertrophic osteoarthropathy, is a rare syndrome that can be inherited as autosomal dominant, autosomal recessive, or sporadically. This progressive disease primarily affects males, who tend to have more severe features than females. PDP usually occurs during adolescence, often starting around puberty.1 The main clinical features are…
Study Assesses Sarilumab for Polymyalgia Rheumatica
In an ACR Convergence 2022 session, Robert Spiera, MD, director of the Scleroderma, Vasculitis, and Myositis Center at the Hospital for Special Surgery, New York City, discussed the use of sarilumab as a potential glucocorticoid-sparing therapy in a phase 3 study in patients with treatment-refractory polymyalgia rheumatica (PMR), one of the most common inflammatory diseases…
How to Treat Refractory Polymyalgia Rheumatica
Patients with polymyalgia rheumatica (PMR) who had relapsed while tapering glucocorticoid therapy were more likely to achieve sustained remission at one year and have a lower glucocorticoid exposure if they were treated with sarilumab (Kevzara) plus a rapid, 14-week glucocorticoid taper than if they received placebo plus a standard, 52-week glucocorticoid taper. This is according…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 36
- Next Page »